Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2020

View Archived Issues

Depression's structural problem

Modeling the post-infarct heart

Narrower interferon activity could benefit immune therapy

Fetal pharmacotherapy in the developing inner ear may rescue congenital deafness

Researchers find mutated ATP10B to increase risk of Parkinson's disease

SOM Biotech identifies three drug candidates for COVID-19

First patient dosed in global study of low-dose selinexor in severe COVID-19

Encouraging data reported for Ruconest in patients with COVID-19

Novel IL-27-based targeting gene therapy shows promise in prostate cancer models

Novel ferret model of infection and rapid transmission of SARS-CoV-2

Neobiotek divulges new DPP-IV inhibitors

Genentech and Roche present MAP4K1 inhibitors

Kubota Pharmaceutical Holdings synthesizes AOC3 inhibitors

LG Chem discloses ketohexokinase inhibitors

Japanese researchers synthesize compounds for Ebola virus infection

Harbour BioMed initiates phase Ib/IIa study of batoclimab in NMOSD

Phase II trial of Tesomet in hypothalamic obesity shows improvements on key efficacy endpoints

Enrollment complete in INSIGHT-004 study of eftilagimod alpha with avelumab in advanced solid tumors

Arcutis initiates phase I/IIb study of ARQ-252 for chronic hand eczema

FDA approves Imbruvica with rituximab for previously untreated CLL or SLL

Tempest enrolling in phase Ia/Ib study of TPST-1495 for advanced solid tumors

New model shows role of Pin1 in neuronal excitability and cognitive flexibility

FDA accepts IND for study of ATYR-1923 for COVID-19 patients with severe respiratory complications

IRE1-alpha deletion protects from type 1 diabetes through beta cell dedifferentiation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...